1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Primary Immunodeficiency Drug Annual Sales 2020-2031 2.1.2 World Current & Future Analysis for Primary Immunodeficiency Drug by Geographic Region, 2020, 2024 & 2031 2.1.3 World Current & Future Analysis for Primary Immunodeficiency Drug by Country/Region, 2020, 2024 & 2031 2.2 Primary Immunodeficiency Drug Segment by Type 2.2.1 Immunoglobulin 2.2.2 Antibiotic 2.2.3 Stem Cell 2.2.4 Other 2.3 Primary Immunodeficiency Drug Sales by Type 2.3.1 Global Primary Immunodeficiency Drug Sales Market Share by Type (2020-2025) 2.3.2 Global Primary Immunodeficiency Drug Revenue and Market Share by Type (2020-2025) 2.3.3 Global Primary Immunodeficiency Drug Sale Price by Type (2020-2025) 2.4 Primary Immunodeficiency Drug Segment by Application 2.4.1 Antibody Deficiency 2.4.2 Cellular Immunodeficiency 2.4.3 Innate Immune Disease 2.4.4 Other 2.5 Primary Immunodeficiency Drug Sales by Application 2.5.1 Global Primary Immunodeficiency Drug Sale Market Share by Application (2020-2025) 2.5.2 Global Primary Immunodeficiency Drug Revenue and Market Share by Application (2020-2025) 2.5.3 Global Primary Immunodeficiency Drug Sale Price by Application (2020-2025) 3 Global by Company 3.1 Global Primary Immunodeficiency Drug Breakdown Data by Company 3.1.1 Global Primary Immunodeficiency Drug Annual Sales by Company (2020-2025) 3.1.2 Global Primary Immunodeficiency Drug Sales Market Share by Company (2020-2025) 3.2 Global Primary Immunodeficiency Drug Annual Revenue by Company (2020-2025) 3.2.1 Global Primary Immunodeficiency Drug Revenue by Company (2020-2025) 3.2.2 Global Primary Immunodeficiency Drug Revenue Market Share by Company (2020-2025) 3.3 Global Primary Immunodeficiency Drug Sale Price by Company 3.4 Key Manufacturers Primary Immunodeficiency Drug Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Primary Immunodeficiency Drug Product Location Distribution 3.4.2 Players Primary Immunodeficiency Drug Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Primary Immunodeficiency Drug by Geographic Region 4.1 World Historic Primary Immunodeficiency Drug Market Size by Geographic Region (2020-2025) 4.1.1 Global Primary Immunodeficiency Drug Annual Sales by Geographic Region (2020-2025) 4.1.2 Global Primary Immunodeficiency Drug Annual Revenue by Geographic Region (2020-2025) 4.2 World Historic Primary Immunodeficiency Drug Market Size by Country/Region (2020-2025) 4.2.1 Global Primary Immunodeficiency Drug Annual Sales by Country/Region (2020-2025) 4.2.2 Global Primary Immunodeficiency Drug Annual Revenue by Country/Region (2020-2025) 4.3 Americas Primary Immunodeficiency Drug Sales Growth 4.4 APAC Primary Immunodeficiency Drug Sales Growth 4.5 Europe Primary Immunodeficiency Drug Sales Growth 4.6 Middle East & Africa Primary Immunodeficiency Drug Sales Growth 5 Americas 5.1 Americas Primary Immunodeficiency Drug Sales by Country 5.1.1 Americas Primary Immunodeficiency Drug Sales by Country (2020-2025) 5.1.2 Americas Primary Immunodeficiency Drug Revenue by Country (2020-2025) 5.2 Americas Primary Immunodeficiency Drug Sales by Type (2020-2025) 5.3 Americas Primary Immunodeficiency Drug Sales by Application (2020-2025) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Primary Immunodeficiency Drug Sales by Region 6.1.1 APAC Primary Immunodeficiency Drug Sales by Region (2020-2025) 6.1.2 APAC Primary Immunodeficiency Drug Revenue by Region (2020-2025) 6.2 APAC Primary Immunodeficiency Drug Sales by Type (2020-2025) 6.3 APAC Primary Immunodeficiency Drug Sales by Application (2020-2025) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Primary Immunodeficiency Drug by Country 7.1.1 Europe Primary Immunodeficiency Drug Sales by Country (2020-2025) 7.1.2 Europe Primary Immunodeficiency Drug Revenue by Country (2020-2025) 7.2 Europe Primary Immunodeficiency Drug Sales by Type (2020-2025) 7.3 Europe Primary Immunodeficiency Drug Sales by Application (2020-2025) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Primary Immunodeficiency Drug by Country 8.1.1 Middle East & Africa Primary Immunodeficiency Drug Sales by Country (2020-2025) 8.1.2 Middle East & Africa Primary Immunodeficiency Drug Revenue by Country (2020-2025) 8.2 Middle East & Africa Primary Immunodeficiency Drug Sales by Type (2020-2025) 8.3 Middle East & Africa Primary Immunodeficiency Drug Sales by Application (2020-2025) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Primary Immunodeficiency Drug 10.3 Manufacturing Process Analysis of Primary Immunodeficiency Drug 10.4 Industry Chain Structure of Primary Immunodeficiency Drug 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Primary Immunodeficiency Drug Distributors 11.3 Primary Immunodeficiency Drug Customer 12 World Forecast Review for Primary Immunodeficiency Drug by Geographic Region 12.1 Global Primary Immunodeficiency Drug Market Size Forecast by Region 12.1.1 Global Primary Immunodeficiency Drug Forecast by Region (2026-2031) 12.1.2 Global Primary Immunodeficiency Drug Annual Revenue Forecast by Region (2026-2031) 12.2 Americas Forecast by Country (2026-2031) 12.3 APAC Forecast by Region (2026-2031) 12.4 Europe Forecast by Country (2026-2031) 12.5 Middle East & Africa Forecast by Country (2026-2031) 12.6 Global Primary Immunodeficiency Drug Forecast by Type (2026-2031) 12.7 Global Primary Immunodeficiency Drug Forecast by Application (2026-2031) 13 Key Players Analysis 13.1 ADMA Biologics, Inc. 13.1.1 ADMA Biologics, Inc. Company Information 13.1.2 ADMA Biologics, Inc. Primary Immunodeficiency Drug Product Portfolios and Specifications 13.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.1.4 ADMA Biologics, Inc. Main Business Overview 13.1.5 ADMA Biologics, Inc. Latest Developments 13.2 CSL Behring, LLC 13.2.1 CSL Behring, LLC Company Information 13.2.2 CSL Behring, LLC Primary Immunodeficiency Drug Product Portfolios and Specifications 13.2.3 CSL Behring, LLC Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.2.4 CSL Behring, LLC Main Business Overview 13.2.5 CSL Behring, LLC Latest Developments 13.3 Octapharma 13.3.1 Octapharma Company Information 13.3.2 Octapharma Primary Immunodeficiency Drug Product Portfolios and Specifications 13.3.3 Octapharma Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.3.4 Octapharma Main Business Overview 13.3.5 Octapharma Latest Developments 13.4 Takeda Pharmaceutical Company 13.4.1 Takeda Pharmaceutical Company Company Information 13.4.2 Takeda Pharmaceutical Company Primary Immunodeficiency Drug Product Portfolios and Specifications 13.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.4.4 Takeda Pharmaceutical Company Main Business Overview 13.4.5 Takeda Pharmaceutical Company Latest Developments 13.5 Grifols Biologicals, Inc. 13.5.1 Grifols Biologicals, Inc. Company Information 13.5.2 Grifols Biologicals, Inc. Primary Immunodeficiency Drug Product Portfolios and Specifications 13.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.5.4 Grifols Biologicals, Inc. Main Business Overview 13.5.5 Grifols Biologicals, Inc. Latest Developments 13.6 Baxter 13.6.1 Baxter Company Information 13.6.2 Baxter Primary Immunodeficiency Drug Product Portfolios and Specifications 13.6.3 Baxter Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.6.4 Baxter Main Business Overview 13.6.5 Baxter Latest Developments 13.7 Kedrion Biopharma 13.7.1 Kedrion Biopharma Company Information 13.7.2 Kedrion Biopharma Primary Immunodeficiency Drug Product Portfolios and Specifications 13.7.3 Kedrion Biopharma Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.7.4 Kedrion Biopharma Main Business Overview 13.7.5 Kedrion Biopharma Latest Developments 13.8 BPL Inc. 13.8.1 BPL Inc. Company Information 13.8.2 BPL Inc. Primary Immunodeficiency Drug Product Portfolios and Specifications 13.8.3 BPL Inc. Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.8.4 BPL Inc. Main Business Overview 13.8.5 BPL Inc. Latest Developments 13.9 Pharming Group 13.9.1 Pharming Group Company Information 13.9.2 Pharming Group Primary Immunodeficiency Drug Product Portfolios and Specifications 13.9.3 Pharming Group Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.9.4 Pharming Group Main Business Overview 13.9.5 Pharming Group Latest Developments 13.10 Shire 13.10.1 Shire Company Information 13.10.2 Shire Primary Immunodeficiency Drug Product Portfolios and Specifications 13.10.3 Shire Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.10.4 Shire Main Business Overview 13.10.5 Shire Latest Developments 13.11 Chengdu Rongsheng Pharmaceutical Co., Ltd 13.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Company Information 13.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Product Portfolios and Specifications 13.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Sales, Revenue, Price and Gross Margin (2020-2025) 13.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Main Business Overview 13.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Latest Developments 14 Research Findings and Conclusion
List of Tables Table 1. Primary Immunodeficiency Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions) Table 2. Primary Immunodeficiency Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions) Table 3. Major Players of Immunoglobulin Table 4. Major Players of Antibiotic Table 5. Major Players of Stem Cell Table 6. Major Players of Other Table 7. Global Primary Immunodeficiency Drug Sales by Type (2020-2025) & (K Units) Table 8. Global Primary Immunodeficiency Drug Sales Market Share by Type (2020-2025) Table 9. Global Primary Immunodeficiency Drug Revenue by Type (2020-2025) & ($ million) Table 10. Global Primary Immunodeficiency Drug Revenue Market Share by Type (2020-2025) Table 11. Global Primary Immunodeficiency Drug Sale Price by Type (2020-2025) & (US$/Unit) Table 12. Global Primary Immunodeficiency Drug Sale by Application (2020-2025) & (K Units) Table 13. Global Primary Immunodeficiency Drug Sale Market Share by Application (2020-2025) Table 14. Global Primary Immunodeficiency Drug Revenue by Application (2020-2025) & ($ million) Table 15. Global Primary Immunodeficiency Drug Revenue Market Share by Application (2020-2025) Table 16. Global Primary Immunodeficiency Drug Sale Price by Application (2020-2025) & (US$/Unit) Table 17. Global Primary Immunodeficiency Drug Sales by Company (2020-2025) & (K Units) Table 18. Global Primary Immunodeficiency Drug Sales Market Share by Company (2020-2025) Table 19. Global Primary Immunodeficiency Drug Revenue by Company (2020-2025) & ($ millions) Table 20. Global Primary Immunodeficiency Drug Revenue Market Share by Company (2020-2025) Table 21. Global Primary Immunodeficiency Drug Sale Price by Company (2020-2025) & (US$/Unit) Table 22. Key Manufacturers Primary Immunodeficiency Drug Producing Area Distribution and Sales Area Table 23. Players Primary Immunodeficiency Drug Products Offered Table 24. Primary Immunodeficiency Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) Table 25. New Products and Potential Entrants Table 26. Market M&A Activity & Strategy Table 27. Global Primary Immunodeficiency Drug Sales by Geographic Region (2020-2025) & (K Units) Table 28. Global Primary Immunodeficiency Drug Sales Market Share Geographic Region (2020-2025) Table 29. Global Primary Immunodeficiency Drug Revenue by Geographic Region (2020-2025) & ($ millions) Table 30. Global Primary Immunodeficiency Drug Revenue Market Share by Geographic Region (2020-2025) Table 31. Global Primary Immunodeficiency Drug Sales by Country/Region (2020-2025) & (K Units) Table 32. Global Primary Immunodeficiency Drug Sales Market Share by Country/Region (2020-2025) Table 33. Global Primary Immunodeficiency Drug Revenue by Country/Region (2020-2025) & ($ millions) Table 34. Global Primary Immunodeficiency Drug Revenue Market Share by Country/Region (2020-2025) Table 35. Americas Primary Immunodeficiency Drug Sales by Country (2020-2025) & (K Units) Table 36. Americas Primary Immunodeficiency Drug Sales Market Share by Country (2020-2025) Table 37. Americas Primary Immunodeficiency Drug Revenue by Country (2020-2025) & ($ millions) Table 38. Americas Primary Immunodeficiency Drug Sales by Type (2020-2025) & (K Units) Table 39. Americas Primary Immunodeficiency Drug Sales by Application (2020-2025) & (K Units) Table 40. APAC Primary Immunodeficiency Drug Sales by Region (2020-2025) & (K Units) Table 41. APAC Primary Immunodeficiency Drug Sales Market Share by Region (2020-2025) Table 42. APAC Primary Immunodeficiency Drug Revenue by Region (2020-2025) & ($ millions) Table 43. APAC Primary Immunodeficiency Drug Sales by Type (2020-2025) & (K Units) Table 44. APAC Primary Immunodeficiency Drug Sales by Application (2020-2025) & (K Units) Table 45. Europe Primary Immunodeficiency Drug Sales by Country (2020-2025) & (K Units) Table 46. Europe Primary Immunodeficiency Drug Revenue by Country (2020-2025) & ($ millions) Table 47. Europe Primary Immunodeficiency Drug Sales by Type (2020-2025) & (K Units) Table 48. Europe Primary Immunodeficiency Drug Sales by Application (2020-2025) & (K Units) Table 49. Middle East & Africa Primary Immunodeficiency Drug Sales by Country (2020-2025) & (K Units) Table 50. Middle East & Africa Primary Immunodeficiency Drug Revenue Market Share by Country (2020-2025) Table 51. Middle East & Africa Primary Immunodeficiency Drug Sales by Type (2020-2025) & (K Units) Table 52. Middle East & Africa Primary Immunodeficiency Drug Sales by Application (2020-2025) & (K Units) Table 53. Key Market Drivers & Growth Opportunities of Primary Immunodeficiency Drug Table 54. Key Market Challenges & Risks of Primary Immunodeficiency Drug Table 55. Key Industry Trends of Primary Immunodeficiency Drug Table 56. Primary Immunodeficiency Drug Raw Material Table 57. Key Suppliers of Raw Materials Table 58. Primary Immunodeficiency Drug Distributors List Table 59. Primary Immunodeficiency Drug Customer List Table 60. Global Primary Immunodeficiency Drug Sales Forecast by Region (2026-2031) & (K Units) Table 61. Global Primary Immunodeficiency Drug Revenue Forecast by Region (2026-2031) & ($ millions) Table 62. Americas Primary Immunodeficiency Drug Sales Forecast by Country (2026-2031) & (K Units) Table 63. Americas Primary Immunodeficiency Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions) Table 64. APAC Primary Immunodeficiency Drug Sales Forecast by Region (2026-2031) & (K Units) Table 65. APAC Primary Immunodeficiency Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions) Table 66. Europe Primary Immunodeficiency Drug Sales Forecast by Country (2026-2031) & (K Units) Table 67. Europe Primary Immunodeficiency Drug Revenue Forecast by Country (2026-2031) & ($ millions) Table 68. Middle East & Africa Primary Immunodeficiency Drug Sales Forecast by Country (2026-2031) & (K Units) Table 69. Middle East & Africa Primary Immunodeficiency Drug Revenue Forecast by Country (2026-2031) & ($ millions) Table 70. Global Primary Immunodeficiency Drug Sales Forecast by Type (2026-2031) & (K Units) Table 71. Global Primary Immunodeficiency Drug Revenue Forecast by Type (2026-2031) & ($ millions) Table 72. Global Primary Immunodeficiency Drug Sales Forecast by Application (2026-2031) & (K Units) Table 73. Global Primary Immunodeficiency Drug Revenue Forecast by Application (2026-2031) & ($ millions) Table 74. ADMA Biologics, Inc. Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 75. ADMA Biologics, Inc. Primary Immunodeficiency Drug Product Portfolios and Specifications Table 76. ADMA Biologics, Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 77. ADMA Biologics, Inc. Main Business Table 78. ADMA Biologics, Inc. Latest Developments Table 79. CSL Behring, LLC Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 80. CSL Behring, LLC Primary Immunodeficiency Drug Product Portfolios and Specifications Table 81. CSL Behring, LLC Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 82. CSL Behring, LLC Main Business Table 83. CSL Behring, LLC Latest Developments Table 84. Octapharma Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 85. Octapharma Primary Immunodeficiency Drug Product Portfolios and Specifications Table 86. Octapharma Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 87. Octapharma Main Business Table 88. Octapharma Latest Developments Table 89. Takeda Pharmaceutical Company Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 90. Takeda Pharmaceutical Company Primary Immunodeficiency Drug Product Portfolios and Specifications Table 91. Takeda Pharmaceutical Company Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 92. Takeda Pharmaceutical Company Main Business Table 93. Takeda Pharmaceutical Company Latest Developments Table 94. Grifols Biologicals, Inc. Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 95. Grifols Biologicals, Inc. Primary Immunodeficiency Drug Product Portfolios and Specifications Table 96. Grifols Biologicals, Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 97. Grifols Biologicals, Inc. Main Business Table 98. Grifols Biologicals, Inc. Latest Developments Table 99. Baxter Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 100. Baxter Primary Immunodeficiency Drug Product Portfolios and Specifications Table 101. Baxter Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 102. Baxter Main Business Table 103. Baxter Latest Developments Table 104. Kedrion Biopharma Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 105. Kedrion Biopharma Primary Immunodeficiency Drug Product Portfolios and Specifications Table 106. Kedrion Biopharma Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 107. Kedrion Biopharma Main Business Table 108. Kedrion Biopharma Latest Developments Table 109. BPL Inc. Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 110. BPL Inc. Primary Immunodeficiency Drug Product Portfolios and Specifications Table 111. BPL Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 112. BPL Inc. Main Business Table 113. BPL Inc. Latest Developments Table 114. Pharming Group Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 115. Pharming Group Primary Immunodeficiency Drug Product Portfolios and Specifications Table 116. Pharming Group Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 117. Pharming Group Main Business Table 118. Pharming Group Latest Developments Table 119. Shire Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 120. Shire Primary Immunodeficiency Drug Product Portfolios and Specifications Table 121. Shire Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 122. Shire Main Business Table 123. Shire Latest Developments Table 124. Chengdu Rongsheng Pharmaceutical Co., Ltd Basic Information, Primary Immunodeficiency Drug Manufacturing Base, Sales Area and Its Competitors Table 125. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Product Portfolios and Specifications Table 126. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 127. Chengdu Rongsheng Pharmaceutical Co., Ltd Main Business Table 128. Chengdu Rongsheng Pharmaceutical Co., Ltd Latest Developments List of Figures Figure 1. Picture of Primary Immunodeficiency Drug Figure 2. Primary Immunodeficiency Drug Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Primary Immunodeficiency Drug Sales Growth Rate 2020-2031 (K Units) Figure 7. Global Primary Immunodeficiency Drug Revenue Growth Rate 2020-2031 ($ millions) Figure 8. Primary Immunodeficiency Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions) Figure 9. Primary Immunodeficiency Drug Sales Market Share by Country/Region (2024) Figure 10. Primary Immunodeficiency Drug Sales Market Share by Country/Region (2020, 2024 & 2031) Figure 11. Product Picture of Immunoglobulin Figure 12. Product Picture of Antibiotic Figure 13. Product Picture of Stem Cell Figure 14. Product Picture of Other Figure 15. Global Primary Immunodeficiency Drug Sales Market Share by Type in 2025 Figure 16. Global Primary Immunodeficiency Drug Revenue Market Share by Type (2020-2025) Figure 17. Primary Immunodeficiency Drug Consumed in Antibody Deficiency Figure 18. Global Primary Immunodeficiency Drug Market: Antibody Deficiency (2020-2025) & (K Units) Figure 19. Primary Immunodeficiency Drug Consumed in Cellular Immunodeficiency Figure 20. Global Primary Immunodeficiency Drug Market: Cellular Immunodeficiency (2020-2025) & (K Units) Figure 21. Primary Immunodeficiency Drug Consumed in Innate Immune Disease Figure 22. Global Primary Immunodeficiency Drug Market: Innate Immune Disease (2020-2025) & (K Units) Figure 23. Primary Immunodeficiency Drug Consumed in Other Figure 24. Global Primary Immunodeficiency Drug Market: Other (2020-2025) & (K Units) Figure 25. Global Primary Immunodeficiency Drug Sale Market Share by Application (2024) Figure 26. Global Primary Immunodeficiency Drug Revenue Market Share by Application in 2025 Figure 27. Primary Immunodeficiency Drug Sales by Company in 2025 (K Units) Figure 28. Global Primary Immunodeficiency Drug Sales Market Share by Company in 2025 Figure 29. Primary Immunodeficiency Drug Revenue by Company in 2025 ($ millions) Figure 30. Global Primary Immunodeficiency Drug Revenue Market Share by Company in 2025 Figure 31. Global Primary Immunodeficiency Drug Sales Market Share by Geographic Region (2020-2025) Figure 32. Global Primary Immunodeficiency Drug Revenue Market Share by Geographic Region in 2025 Figure 33. Americas Primary Immunodeficiency Drug Sales 2020-2025 (K Units) Figure 34. Americas Primary Immunodeficiency Drug Revenue 2020-2025 ($ millions) Figure 35. APAC Primary Immunodeficiency Drug Sales 2020-2025 (K Units) Figure 36. APAC Primary Immunodeficiency Drug Revenue 2020-2025 ($ millions) Figure 37. Europe Primary Immunodeficiency Drug Sales 2020-2025 (K Units) Figure 38. Europe Primary Immunodeficiency Drug Revenue 2020-2025 ($ millions) Figure 39. Middle East & Africa Primary Immunodeficiency Drug Sales 2020-2025 (K Units) Figure 40. Middle East & Africa Primary Immunodeficiency Drug Revenue 2020-2025 ($ millions) Figure 41. Americas Primary Immunodeficiency Drug Sales Market Share by Country in 2025 Figure 42. Americas Primary Immunodeficiency Drug Revenue Market Share by Country (2020-2025) Figure 43. Americas Primary Immunodeficiency Drug Sales Market Share by Type (2020-2025) Figure 44. Americas Primary Immunodeficiency Drug Sales Market Share by Application (2020-2025) Figure 45. United States Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 46. Canada Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 47. Mexico Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 48. Brazil Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 49. APAC Primary Immunodeficiency Drug Sales Market Share by Region in 2025 Figure 50. APAC Primary Immunodeficiency Drug Revenue Market Share by Region (2020-2025) Figure 51. APAC Primary Immunodeficiency Drug Sales Market Share by Type (2020-2025) Figure 52. APAC Primary Immunodeficiency Drug Sales Market Share by Application (2020-2025) Figure 53. China Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 54. Japan Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 55. South Korea Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 56. Southeast Asia Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 57. India Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 58. Australia Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 59. China Taiwan Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 60. Europe Primary Immunodeficiency Drug Sales Market Share by Country in 2025 Figure 61. Europe Primary Immunodeficiency Drug Revenue Market Share by Country (2020-2025) Figure 62. Europe Primary Immunodeficiency Drug Sales Market Share by Type (2020-2025) Figure 63. Europe Primary Immunodeficiency Drug Sales Market Share by Application (2020-2025) Figure 64. Germany Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 65. France Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 66. UK Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 67. Italy Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 68. Russia Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 69. Middle East & Africa Primary Immunodeficiency Drug Sales Market Share by Country (2020-2025) Figure 70. Middle East & Africa Primary Immunodeficiency Drug Sales Market Share by Type (2020-2025) Figure 71. Middle East & Africa Primary Immunodeficiency Drug Sales Market Share by Application (2020-2025) Figure 72. Egypt Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 73. South Africa Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 74. Israel Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 75. Turkey Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 76. GCC Countries Primary Immunodeficiency Drug Revenue Growth 2020-2025 ($ millions) Figure 77. Manufacturing Cost Structure Analysis of Primary Immunodeficiency Drug in 2025 Figure 78. Manufacturing Process Analysis of Primary Immunodeficiency Drug Figure 79. Industry Chain Structure of Primary Immunodeficiency Drug Figure 80. Channels of Distribution Figure 81. Global Primary Immunodeficiency Drug Sales Market Forecast by Region (2026-2031) Figure 82. Global Primary Immunodeficiency Drug Revenue Market Share Forecast by Region (2026-2031) Figure 83. Global Primary Immunodeficiency Drug Sales Market Share Forecast by Type (2026-2031) Figure 84. Global Primary Immunodeficiency Drug Revenue Market Share Forecast by Type (2026-2031) Figure 85. Global Primary Immunodeficiency Drug Sales Market Share Forecast by Application (2026-2031) Figure 86. Global Primary Immunodeficiency Drug Revenue Market Share Forecast by Application (2026-2031)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
ADMA Biologics, Inc.|||CSL Behring, LLC|||Octapharma|||Takeda Pharmaceutical Company|||Grifols Biologicals, Inc.|||Baxter|||Kedrion Biopharma|||BPL Inc.|||Pharming Group|||Shire|||Chengdu Rongsheng Pharmaceutical Co., Ltd